Global Artesunate Drugs Market

Artesunate Drugs Comprehensive Study by Administration (Intravenously, Intramuscularly), Category (Monoaromatic Artesunate, Compound Artesunate), Form (Tablet, Injection, Others), Indication (Malaria, Parasitic Infections, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Third Party Online Sales), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2026

Artesunate Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Artesunate Drugs Market Scope
Malaria remains a tremendous health burden in tropical areas causing majority deaths in such regions. Severe malaria is mostly a pediatric illness, and fatality in children frequently occurs within the first 24 hours of admission, limiting the temporal window for AS to provide a therapeutic benefit. New medicines like intravenous artesunate (AS) and intramuscular artemether (AM) are reducing malaria fatalities and improving results. Artesunate is a water-soluble semisynthetic derivative of artemisinin that has an advantage over other artemisinins in that it may be produced as oral, rectal, intramuscular, and intravenous formulations. Dihydroartemisinin, the most potent schizonticidal metabolite, is quickly hydrolyzed from artesunate. When opposed to intramuscular AM, injectable AS has a faster systemic availability. This pharmacokinetic benefit might be helpful in the treatment of severe and complex malaria.

The Artesunate Drugs market study is segmented and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that Indian Players will contribute to the maximum growth of Global Artesunate Drugs market throughout the predicted period.

Fosun Pharma (China), Ipca Laboratories (India), Sanofi S.A. (France), Ajanta Pharma (India), Shin Poong Pharm.Co.,Ltd. (South Korea), Cipla Limited (India), Acino Holding (Switzerland), MCW Healthcare (India) and Amivas (US), LLC (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Artesunate Drugs market by Type, Application and Region.

On the basis of geography, the market of Artesunate Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 27th May, 2021 - Amivas (US), LLC Announced US Food and Drug Administration (FDA) Approval of its “Artesunate for Injection” 110 mg, Powder and Solvent for Solution in Treatment of Severe Malaria which Allows Amivas to Manufacture, Distribute and Commercialize Artesunate for Injection. and On 16th November, 2017 - Cipla Launched Combination Anti-Malarial Drug in Africa, South-East Asian Countries. The Drug-Resistant Falciparum Malaria Two-In-One Combination (Artesunate (AS) And Mefloquine (MQ) Was Developed in Cooperation with The Drugs for Neglected Diseases Initiative (DNDi).


Market Trend
  • Growing Healthcare Infrastructure

Market Drivers
  • Prevalence of Malaria in Pediatric Population
  • Rising Geriatric Population

Opportunities
  • Increasing Demand Across African Regions
  • High Expenditure in Pharma R&D

Restraints
  • Lack of Trained Professionals
  • Side Effects and Adverse Reactions

Challenges
  • Skewed Player Distribution


Key Target Audience
Artesunate Drugs Manufactures, New Entrants and Investors, Artesunate Drugs Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Administration
  • Intravenously
  • Intramuscularly

By Category
  • Monoaromatic Artesunate
  • Compound Artesunate

By Form
  • Tablet
  • Injection
  • Others

By Indication
  • Malaria
  • Parasitic Infections
  • Others

By Distribution
  • Hospital Dispensaries
  • Retail Pharmacies
  • Third Party Online Sales

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Malaria in Pediatric Population
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Skewed Player Distribution
    • 3.4. Market Trends
      • 3.4.1. Growing Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Artesunate Drugs, by Administration, Category, Form, Indication, Distribution, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Artesunate Drugs (Value)
      • 5.2.1. Global Artesunate Drugs by: Administration (Value)
        • 5.2.1.1. Intravenously
        • 5.2.1.2. Intramuscularly
      • 5.2.2. Global Artesunate Drugs by: Category (Value)
        • 5.2.2.1. Monoaromatic Artesunate
        • 5.2.2.2. Compound Artesunate
      • 5.2.3. Global Artesunate Drugs by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Injection
        • 5.2.3.3. Others
      • 5.2.4. Global Artesunate Drugs by: Indication (Value)
        • 5.2.4.1. Malaria
        • 5.2.4.2. Parasitic Infections
        • 5.2.4.3. Others
      • 5.2.5. Global Artesunate Drugs by: Distribution (Value)
        • 5.2.5.1. Hospital Dispensaries
        • 5.2.5.2. Retail Pharmacies
        • 5.2.5.3. Third Party Online Sales
      • 5.2.6. Global Artesunate Drugs by: End User (Value)
        • 5.2.6.1. Pediatric
        • 5.2.6.2. Adult
        • 5.2.6.3. Geriatric
      • 5.2.7. Global Artesunate Drugs Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Artesunate Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fosun Pharma (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Ipca Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ajanta Pharma (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shin Poong Pharm.Co.,Ltd. (South Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cipla Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Acino Holding (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MCW Healthcare (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amivas (US), LLC (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Artesunate Drugs Sale, by Administration, Category, Form, Indication, Distribution, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Artesunate Drugs (Value)
      • 7.2.1. Global Artesunate Drugs by: Administration (Value)
        • 7.2.1.1. Intravenously
        • 7.2.1.2. Intramuscularly
      • 7.2.2. Global Artesunate Drugs by: Category (Value)
        • 7.2.2.1. Monoaromatic Artesunate
        • 7.2.2.2. Compound Artesunate
      • 7.2.3. Global Artesunate Drugs by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Injection
        • 7.2.3.3. Others
      • 7.2.4. Global Artesunate Drugs by: Indication (Value)
        • 7.2.4.1. Malaria
        • 7.2.4.2. Parasitic Infections
        • 7.2.4.3. Others
      • 7.2.5. Global Artesunate Drugs by: Distribution (Value)
        • 7.2.5.1. Hospital Dispensaries
        • 7.2.5.2. Retail Pharmacies
        • 7.2.5.3. Third Party Online Sales
      • 7.2.6. Global Artesunate Drugs by: End User (Value)
        • 7.2.6.1. Pediatric
        • 7.2.6.2. Adult
        • 7.2.6.3. Geriatric
      • 7.2.7. Global Artesunate Drugs Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Artesunate Drugs: by Administration(USD Million)
  • Table 2. Artesunate Drugs Intravenously , by Region USD Million (2015-2020)
  • Table 3. Artesunate Drugs Intramuscularly , by Region USD Million (2015-2020)
  • Table 4. Artesunate Drugs: by Category(USD Million)
  • Table 5. Artesunate Drugs Monoaromatic Artesunate , by Region USD Million (2015-2020)
  • Table 6. Artesunate Drugs Compound Artesunate , by Region USD Million (2015-2020)
  • Table 7. Artesunate Drugs: by Form(USD Million)
  • Table 8. Artesunate Drugs Tablet , by Region USD Million (2015-2020)
  • Table 9. Artesunate Drugs Injection , by Region USD Million (2015-2020)
  • Table 10. Artesunate Drugs Others , by Region USD Million (2015-2020)
  • Table 11. Artesunate Drugs: by Indication(USD Million)
  • Table 12. Artesunate Drugs Malaria , by Region USD Million (2015-2020)
  • Table 13. Artesunate Drugs Parasitic Infections , by Region USD Million (2015-2020)
  • Table 14. Artesunate Drugs Others , by Region USD Million (2015-2020)
  • Table 15. Artesunate Drugs: by Distribution(USD Million)
  • Table 16. Artesunate Drugs Hospital Dispensaries , by Region USD Million (2015-2020)
  • Table 17. Artesunate Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 18. Artesunate Drugs Third Party Online Sales , by Region USD Million (2015-2020)
  • Table 19. Artesunate Drugs: by End User(USD Million)
  • Table 20. Artesunate Drugs Pediatric , by Region USD Million (2015-2020)
  • Table 21. Artesunate Drugs Adult , by Region USD Million (2015-2020)
  • Table 22. Artesunate Drugs Geriatric , by Region USD Million (2015-2020)
  • Table 23. South America Artesunate Drugs, by Country USD Million (2015-2020)
  • Table 24. South America Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 25. South America Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 26. South America Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 27. South America Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 28. South America Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 29. South America Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 30. Brazil Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 31. Brazil Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 32. Brazil Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 33. Brazil Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 34. Brazil Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 35. Brazil Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 36. Argentina Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 37. Argentina Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 38. Argentina Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 39. Argentina Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 40. Argentina Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 41. Argentina Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 42. Rest of South America Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 43. Rest of South America Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 44. Rest of South America Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 45. Rest of South America Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 46. Rest of South America Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 47. Rest of South America Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 48. Asia Pacific Artesunate Drugs, by Country USD Million (2015-2020)
  • Table 49. Asia Pacific Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 50. Asia Pacific Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 51. Asia Pacific Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 52. Asia Pacific Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 53. Asia Pacific Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 54. Asia Pacific Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 55. China Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 56. China Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 57. China Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 58. China Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 59. China Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 60. China Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 61. Japan Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 62. Japan Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 63. Japan Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 64. Japan Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 65. Japan Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 66. Japan Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 67. India Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 68. India Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 69. India Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 70. India Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 71. India Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 72. India Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 73. South Korea Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 74. South Korea Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 75. South Korea Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 76. South Korea Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 77. South Korea Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 78. South Korea Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 79. Taiwan Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 80. Taiwan Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 81. Taiwan Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 82. Taiwan Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 83. Taiwan Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 84. Taiwan Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 85. Australia Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 86. Australia Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 87. Australia Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 88. Australia Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 89. Australia Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 90. Australia Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 91. Rest of Asia-Pacific Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 92. Rest of Asia-Pacific Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 93. Rest of Asia-Pacific Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 94. Rest of Asia-Pacific Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 95. Rest of Asia-Pacific Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 96. Rest of Asia-Pacific Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 97. Europe Artesunate Drugs, by Country USD Million (2015-2020)
  • Table 98. Europe Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 99. Europe Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 100. Europe Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 101. Europe Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 102. Europe Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 103. Europe Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 104. Germany Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 105. Germany Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 106. Germany Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 107. Germany Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 108. Germany Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 109. Germany Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 110. France Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 111. France Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 112. France Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 113. France Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 114. France Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 115. France Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 116. Italy Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 117. Italy Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 118. Italy Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 119. Italy Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 120. Italy Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 121. Italy Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 122. United Kingdom Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 123. United Kingdom Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 124. United Kingdom Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 125. United Kingdom Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 126. United Kingdom Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 127. United Kingdom Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 128. Netherlands Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 129. Netherlands Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 130. Netherlands Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 131. Netherlands Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 132. Netherlands Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 133. Netherlands Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 134. Rest of Europe Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 135. Rest of Europe Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 136. Rest of Europe Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 137. Rest of Europe Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 138. Rest of Europe Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 139. Rest of Europe Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 140. MEA Artesunate Drugs, by Country USD Million (2015-2020)
  • Table 141. MEA Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 142. MEA Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 143. MEA Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 144. MEA Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 145. MEA Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 146. MEA Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 147. Middle East Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 148. Middle East Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 149. Middle East Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 150. Middle East Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 151. Middle East Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 152. Middle East Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 153. Africa Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 154. Africa Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 155. Africa Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 156. Africa Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 157. Africa Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 158. Africa Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 159. North America Artesunate Drugs, by Country USD Million (2015-2020)
  • Table 160. North America Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 161. North America Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 162. North America Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 163. North America Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 164. North America Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 165. North America Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 166. United States Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 167. United States Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 168. United States Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 169. United States Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 170. United States Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 171. United States Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 172. Canada Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 173. Canada Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 174. Canada Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 175. Canada Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 176. Canada Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 177. Canada Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 178. Mexico Artesunate Drugs, by Administration USD Million (2015-2020)
  • Table 179. Mexico Artesunate Drugs, by Category USD Million (2015-2020)
  • Table 180. Mexico Artesunate Drugs, by Form USD Million (2015-2020)
  • Table 181. Mexico Artesunate Drugs, by Indication USD Million (2015-2020)
  • Table 182. Mexico Artesunate Drugs, by Distribution USD Million (2015-2020)
  • Table 183. Mexico Artesunate Drugs, by End User USD Million (2015-2020)
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Artesunate Drugs: by Administration(USD Million)
  • Table 194. Artesunate Drugs Intravenously , by Region USD Million (2021-2026)
  • Table 195. Artesunate Drugs Intramuscularly , by Region USD Million (2021-2026)
  • Table 196. Artesunate Drugs: by Category(USD Million)
  • Table 197. Artesunate Drugs Monoaromatic Artesunate , by Region USD Million (2021-2026)
  • Table 198. Artesunate Drugs Compound Artesunate , by Region USD Million (2021-2026)
  • Table 199. Artesunate Drugs: by Form(USD Million)
  • Table 200. Artesunate Drugs Tablet , by Region USD Million (2021-2026)
  • Table 201. Artesunate Drugs Injection , by Region USD Million (2021-2026)
  • Table 202. Artesunate Drugs Others , by Region USD Million (2021-2026)
  • Table 203. Artesunate Drugs: by Indication(USD Million)
  • Table 204. Artesunate Drugs Malaria , by Region USD Million (2021-2026)
  • Table 205. Artesunate Drugs Parasitic Infections , by Region USD Million (2021-2026)
  • Table 206. Artesunate Drugs Others , by Region USD Million (2021-2026)
  • Table 207. Artesunate Drugs: by Distribution(USD Million)
  • Table 208. Artesunate Drugs Hospital Dispensaries , by Region USD Million (2021-2026)
  • Table 209. Artesunate Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 210. Artesunate Drugs Third Party Online Sales , by Region USD Million (2021-2026)
  • Table 211. Artesunate Drugs: by End User(USD Million)
  • Table 212. Artesunate Drugs Pediatric , by Region USD Million (2021-2026)
  • Table 213. Artesunate Drugs Adult , by Region USD Million (2021-2026)
  • Table 214. Artesunate Drugs Geriatric , by Region USD Million (2021-2026)
  • Table 215. South America Artesunate Drugs, by Country USD Million (2021-2026)
  • Table 216. South America Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 217. South America Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 218. South America Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 219. South America Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 220. South America Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 221. South America Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 222. Brazil Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 223. Brazil Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 224. Brazil Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 225. Brazil Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 226. Brazil Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 227. Brazil Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 228. Argentina Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 229. Argentina Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 230. Argentina Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 231. Argentina Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 232. Argentina Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 233. Argentina Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 234. Rest of South America Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 235. Rest of South America Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 236. Rest of South America Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 237. Rest of South America Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 238. Rest of South America Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 239. Rest of South America Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 240. Asia Pacific Artesunate Drugs, by Country USD Million (2021-2026)
  • Table 241. Asia Pacific Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 242. Asia Pacific Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 243. Asia Pacific Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 244. Asia Pacific Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 245. Asia Pacific Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 246. Asia Pacific Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 247. China Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 248. China Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 249. China Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 250. China Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 251. China Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 252. China Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 253. Japan Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 254. Japan Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 255. Japan Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 256. Japan Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 257. Japan Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 258. Japan Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 259. India Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 260. India Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 261. India Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 262. India Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 263. India Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 264. India Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 265. South Korea Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 266. South Korea Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 267. South Korea Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 268. South Korea Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 269. South Korea Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 270. South Korea Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 271. Taiwan Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 272. Taiwan Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 273. Taiwan Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 274. Taiwan Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 275. Taiwan Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 276. Taiwan Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 277. Australia Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 278. Australia Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 279. Australia Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 280. Australia Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 281. Australia Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 282. Australia Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 283. Rest of Asia-Pacific Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 284. Rest of Asia-Pacific Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 285. Rest of Asia-Pacific Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 286. Rest of Asia-Pacific Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 287. Rest of Asia-Pacific Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 288. Rest of Asia-Pacific Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 289. Europe Artesunate Drugs, by Country USD Million (2021-2026)
  • Table 290. Europe Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 291. Europe Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 292. Europe Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 293. Europe Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 294. Europe Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 295. Europe Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 296. Germany Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 297. Germany Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 298. Germany Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 299. Germany Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 300. Germany Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 301. Germany Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 302. France Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 303. France Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 304. France Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 305. France Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 306. France Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 307. France Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 308. Italy Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 309. Italy Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 310. Italy Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 311. Italy Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 312. Italy Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 313. Italy Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 314. United Kingdom Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 315. United Kingdom Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 316. United Kingdom Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 317. United Kingdom Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 318. United Kingdom Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 319. United Kingdom Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 320. Netherlands Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 321. Netherlands Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 322. Netherlands Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 323. Netherlands Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 324. Netherlands Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 325. Netherlands Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 326. Rest of Europe Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 327. Rest of Europe Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 328. Rest of Europe Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 329. Rest of Europe Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 330. Rest of Europe Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 331. Rest of Europe Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 332. MEA Artesunate Drugs, by Country USD Million (2021-2026)
  • Table 333. MEA Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 334. MEA Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 335. MEA Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 336. MEA Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 337. MEA Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 338. MEA Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 339. Middle East Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 340. Middle East Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 341. Middle East Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 342. Middle East Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 343. Middle East Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 344. Middle East Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 345. Africa Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 346. Africa Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 347. Africa Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 348. Africa Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 349. Africa Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 350. Africa Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 351. North America Artesunate Drugs, by Country USD Million (2021-2026)
  • Table 352. North America Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 353. North America Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 354. North America Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 355. North America Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 356. North America Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 357. North America Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 358. United States Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 359. United States Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 360. United States Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 361. United States Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 362. United States Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 363. United States Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 364. Canada Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 365. Canada Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 366. Canada Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 367. Canada Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 368. Canada Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 369. Canada Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 370. Mexico Artesunate Drugs, by Administration USD Million (2021-2026)
  • Table 371. Mexico Artesunate Drugs, by Category USD Million (2021-2026)
  • Table 372. Mexico Artesunate Drugs, by Form USD Million (2021-2026)
  • Table 373. Mexico Artesunate Drugs, by Indication USD Million (2021-2026)
  • Table 374. Mexico Artesunate Drugs, by Distribution USD Million (2021-2026)
  • Table 375. Mexico Artesunate Drugs, by End User USD Million (2021-2026)
  • Table 376. Research Programs/Design for This Report
  • Table 377. Key Data Information from Secondary Sources
  • Table 378. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Artesunate Drugs: by Administration USD Million (2015-2020)
  • Figure 5. Global Artesunate Drugs: by Category USD Million (2015-2020)
  • Figure 6. Global Artesunate Drugs: by Form USD Million (2015-2020)
  • Figure 7. Global Artesunate Drugs: by Indication USD Million (2015-2020)
  • Figure 8. Global Artesunate Drugs: by Distribution USD Million (2015-2020)
  • Figure 9. Global Artesunate Drugs: by End User USD Million (2015-2020)
  • Figure 10. South America Artesunate Drugs Share (%), by Country
  • Figure 11. Asia Pacific Artesunate Drugs Share (%), by Country
  • Figure 12. Europe Artesunate Drugs Share (%), by Country
  • Figure 13. MEA Artesunate Drugs Share (%), by Country
  • Figure 14. North America Artesunate Drugs Share (%), by Country
  • Figure 15. Global Artesunate Drugs share by Players 2020 (%)
  • Figure 16. Global Artesunate Drugs share by Players (Top 3) 2020(%)
  • Figure 17. Global Artesunate Drugs share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Fosun Pharma (China) Revenue, Net Income and Gross profit
  • Figure 20. Fosun Pharma (China) Revenue: by Geography 2020
  • Figure 21. Ipca Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 22. Ipca Laboratories (India) Revenue: by Geography 2020
  • Figure 23. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 25. Ajanta Pharma (India) Revenue, Net Income and Gross profit
  • Figure 26. Ajanta Pharma (India) Revenue: by Geography 2020
  • Figure 27. Shin Poong Pharm.Co.,Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. Shin Poong Pharm.Co.,Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 29. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla Limited (India) Revenue: by Geography 2020
  • Figure 31. Acino Holding (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Acino Holding (Switzerland) Revenue: by Geography 2020
  • Figure 33. MCW Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 34. MCW Healthcare (India) Revenue: by Geography 2020
  • Figure 35. Amivas (US), LLC (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amivas (US), LLC (United States) Revenue: by Geography 2020
  • Figure 37. Global Artesunate Drugs: by Administration USD Million (2021-2026)
  • Figure 38. Global Artesunate Drugs: by Category USD Million (2021-2026)
  • Figure 39. Global Artesunate Drugs: by Form USD Million (2021-2026)
  • Figure 40. Global Artesunate Drugs: by Indication USD Million (2021-2026)
  • Figure 41. Global Artesunate Drugs: by Distribution USD Million (2021-2026)
  • Figure 42. Global Artesunate Drugs: by End User USD Million (2021-2026)
  • Figure 43. South America Artesunate Drugs Share (%), by Country
  • Figure 44. Asia Pacific Artesunate Drugs Share (%), by Country
  • Figure 45. Europe Artesunate Drugs Share (%), by Country
  • Figure 46. MEA Artesunate Drugs Share (%), by Country
  • Figure 47. North America Artesunate Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Fosun Pharma (China)
  • Ipca Laboratories (India)
  • Sanofi S.A. (France)
  • Ajanta Pharma (India)
  • Shin Poong Pharm.Co.,Ltd. (South Korea)
  • Cipla Limited (India)
  • Acino Holding (Switzerland)
  • MCW Healthcare (India)
  • Amivas (US), LLC (United States)
Select User Access Type

Key Highlights of Report


Jul 2021 239 Pages 61 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Artesunate Drugs Market Quantitative research analysis
Global Artesunate Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Artesunate Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Prostacyclin Drug Comprehensive Study by Drug (Epoprostenol, Treprostinil, Iloprost, Others), Type (Generic, Branded), End Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Route of Admi...
$ 3750
Eye Balms Comprehensive Study by Type (Medicated, Cosmetic), Application (Sun Protection, Dark Circles, Wrinkles & Anti-Aging, Hydrating, Puffiness, Cleansers, Others) Players and Region - Global Mar...
$ 3500
Amphetamine Drug Comprehensive Study by Type (Generic, Branded), End Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Route of Administration (Oral, Parenteral, Inhalations, Others), Di...
$ 3750
Keytruda Comprehensive Study by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Others), Distribution Channel (Retail, Online), End-User (Hospitals, Clinics) Players and...
$ 3600
Neuromuscular Blocking Drugs Comprehensive Study by Distribution Channel (Online, Offline), End-User (Hospitals, Clinics, Others), Drug Class (Pachycurares, Leptocurares) Players and Region - Global ...
$ 3500
Sarcopenia Supplement Comprehensive Study by Type (Protein Supplement, Vitamin D & Calcium Supplement, Vitamin B12 Supplement), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online ph...
$ 3500